Loading
Black Diamond Therapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 19 Oct 2023.
Black Diamond Therapeutics, Inc.: what insiders have been doing
This page follows insider dealings at Black Diamond Therapeutics, Inc. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. The last twelve months, up to 18 October 2026, brought 8 filings signed by 2 insiders.
Not one of the filings records a straightforward purchase or sale on the market. Grants and option exercises follow pay plans set in advance, so they reveal less about an insider's own view than a purchase made with personal money.
Compared with its exchange (5,811 companies, median 19 filings), a count of 8 filings is below the norm. Our records for Black Diamond Therapeutics, Inc. go back to 2021, with 14 purchases and 3 sales on the open market in total. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists revenue at 70.0 m USD and net income at 22.4 m USD.
No insider has bought Black Diamond Therapeutics, Inc. shares on the open market in the past twelve months. The median gap between a trade and its publication by SEC (Form 4) is 3 days. US insiders must file a Form 4 within two business days of a trade.
In the same sector, recent insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc also feature in our signals. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
85
Thresholds
n/a
Buy Volume
€25M
14 ops. · all time
Sell Volume
€3M
3 ops. · all time
Who traded when
BuySaleGrowth N. Biotech V1 sale
Since the insiders bought
- +52.9%Entry US$2.10 · Close at T+365 US$3.21
- -6.2%Entry US$4.66 · Close at T+365 US$4.37
- -0.9%Entry US$4.41 · Close at T+365 US$4.37
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Black Diamond Therapeutics, Inc. Strong Buy (bullish), based on 7 analysts. Average price target: US$10.00.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 2,148 of 24,148 companies
74.8
score / 100
Value93
Quality57
FCF yld30%
Earn yld23%
EV/EBITDA5.8x
ROE-37%
Gross mgn·
Net mgn32%
Debt/EBITDA0.9x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$1.68
Analyst consensus
7 analystsStrong buy
US$8.00Target US$10.00(+495%)US$14.00
Income statement
RevenueUS$70M
EBITDAUS$20.2M29% margin
Net incomeUS$22.4M32.0% margin
Valuation
PER (forward)-1.7x
P/Book1.0x
Beta3.33
Balance sheet & cash
Market capUS$96.5M
Total debtUS$18.8M
Free Cash FlowUS$29.6M
Debt / Equity18%
Profitability & ownership
ROE-37.2%
ROA-19.1%
% insiders0.7%
% institutions72.6%
Last declaration on 21 September 2026
Declarations85 total
6,801 shares@ US$1.930.012% mcap11.2% of flowCommon StockSEC:0002018686-26-000014:0
7,707 shares@ US$1.930.014% mcap0.3% of flowCommon StockSEC:0001193125-26-396868:0
8,961 sharesCommon StockSEC:0001193125-26-277553:0
7,907 sharesCommon StockSEC:0002018686-26-000008:0
6,919 shares@ US$2.150.3% of flowCommon StockSEC:0001193125-26-117938:0
6,105 shares@ US$2.1511.1% of flowCommon StockSEC:0002018686-26-000002:0
5,208 shares@ US$2.760.3% of flowCommon StockSEC:0001193125-25-319303:0
4,665 shares@ US$2.7610.7% of flowCommon StockSEC:0002018686-25-000007:0
4,291 shares@ US$3.350.3% of flowCommon StockSEC:0001193125-25-211678:0
3,843 shares@ US$3.3510.7% of flowCommon StockSEC:0002018686-25-000004:0
5,526 shares@ US$2.3310.9% of flowCommon StockSEC:0001415889-25-017821:0
6,170 shares@ US$2.330.3% of flowCommon StockSEC:0000950170-25-088527:0
7,646 shares@ US$1.880.3% of flowCommon StockSEC:0000950170-25-043221:0
6,848 shares@ US$1.8811.6% of flowCommon StockSEC:0001415889-25-008771:0
1,000,000 shares@ US$2.069110.4% of flowCommon StockSEC:0001104659-25-026305:0
75,000 shares0Common StockSEC:0001415889-25-002493:0
75,000 shares0Common StockSEC:0001415889-25-002494:0
75,000 shares0Common StockSEC:0001415889-25-002489:0
75,000 shares0Common StockSEC:0001415889-25-002486:0
75,000 shares0Common StockSEC:0001415889-25-002492:0
5,150 shares@ US$2.5012.0% of flowCommon StockSEC:0001415889-24-029482:0
5,750 shares@ US$2.500.3% of flowCommon StockSEC:0000950170-24-136739:0
4,500 shares@ US$2.5035.6% of flowCommon StockSEC:0001415889-24-029481:0
2,694 shares@ US$4.7811.3% of flowCommon StockSEC:0001415889-24-023755:0
3,007 shares@ US$4.780.3% of flowCommon StockSEC:0000950170-24-108430:0
25 of 85 declarations
About Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc. (NASDAQ: BDTX) is a U.S.-listed clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, United States. Founded in 2014 and originally operating under the name ASET Therapeutics, the company repositioned itself around precision oncology and a proprietary discovery platform designed to identify so-called “MasterKey therapies.” In practical terms, Black Diamond seeks to develop small-molecule drugs that can target families of oncogenic mutations rather than a single rare mutation, a strategy that aims to broaden the addressable patient population while maintaining a targeted oncology profile.
For investors, Black Diamond is best understood as a focused biotech story with a high-risk, high-upside profile. The company’s business model is centered on research and clinical development rather than commercialized product sales, which means valuation is driven primarily by clinical data, regulatory milestones, capital runway, and partnering potential. The company has gradually streamlined its pipeline over time, concentrating resources on its most advanced and strategically important program.
Read moreShow less
Its lead asset is silevertinib, an oral, brain-penetrant EGFR inhibitor being developed for EGFR-mutant non-small cell lung cancer, and also evaluated in glioblastoma. That positioning is important: EGFR remains one of the most commercially and clinically relevant targets in oncology, but competition is intense, with multiple large pharmaceutical companies and biotech developers active in the space. Black Diamond’s differentiation lies in the specific mutation-families it addresses and in the company’s attempt to deliver a more comprehensive targeted therapy approach for patient segments that may remain underserved by current standards of care.
The company’s competitive position is therefore selective rather than broad. It is not a diversified oncology platform with multiple marketed assets; instead, it is a development-stage precision medicine company whose upside depends on whether silevertinib can demonstrate meaningful efficacy, acceptable safety, and a clear role in treatment sequencing. If successful, the commercial opportunity could be significant, especially in lung cancer and potentially in CNS-related indications where brain penetration is a valuable feature.
Geographically, Black Diamond’s corporate base is in Cambridge, Massachusetts, while its market listing is on NASDAQ in the United States. The company’s operating footprint is primarily U.S.-centric, although clinical development and future partnering opportunities may naturally extend beyond the domestic market. Recent corporate updates have been important: Black Diamond reported full-year 2025 results in March 2026 and first-quarter 2026 results on May 7, 2026, alongside a corporate update on silevertinib development and the company’s financial position. Those disclosures underscore that the near-term investment case remains tightly linked to clinical progress and cash management.
Overall, Black Diamond Therapeutics is a precision-oncology biotech with a concentrated pipeline, a scientifically differentiated platform, and material execution risk. For French-speaking European investors, it is a classic NASDAQ-listed United States biotech name where the investment thesis hinges on upcoming clinical readouts, regulatory pathway clarity, and the possibility of strategic collaboration or partnering.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
